Commissioner Hahn Self-Quarantines, But US FDA's Operations Will Likely Remain Unaffected

Since most employees already are teleworking, Stephen Hahn’s forced isolation due to potential coronavirus exposure should not cause many disruptions, former FDA officials say.

Stephen Hahn in his 1st address to the FDA January 30, 2020
If FDA Commissioner Stephen Hahn, pictured here in his first address to the FDA on 30 January 2020, stays well and can ensure he remains connected for necessary meetings, he should not be impacted by his coronavirus quarantine, former agency officials said. • Source: FDA

The US Food and Drug Administration’s familiarity with teleworking may mitigate much of the disruption that Commissioner Stephen Hahn’s coronavirus-related quarantine would have caused under normal circumstances.

Hahn announced on 8 May that he would enter two weeks of self-quarantine after learning he came into contact with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.

CAR-T REMS Removal Should Boost Access, But Long-Term Follow-Up, Black Box Remain

 

The REMS removal and labeling changes should open up CAR-T treatment to many more US patients, although other regulatory hurdles and safety language that experts had wanted removed still stand.

PDUFA VIII: Cutting Perceived Conflict Of Interest May Be A Theme

 

Ongoing questions about user fees exerting too much influence over the FDA could spawn a shift in the PDUFA structure when talks begin later this year.

More from Agency Leadership